PEPentwater Capital Management LP
Institutional investor · Portfolio as of Q4 2019
Top Holdings151 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
| 5.6M | $1.8B | 29.4% | — | — | — | Increased — | |
ZAYO GROUP HLDGS INC | 8.7M | $302.5M | 4.9% | — | — | 4 qtrssince 2019-Q1 | Increased 59 |
| 2.5M | $297.1M | 4.9% | — | — | — | Unchanged — | |
AMTD IDEA Group | 5.1M | $252.9M | 4.1% | $50.94 | 0.00% | 1 qtr | New 85 |
| 1.2M | $240.3M | 3.9% | — | — | — | Unchanged — | |
P G & E CORP | 20.9M | $227M | 3.7% | $12.07 | -11.48% | 4 qtrssince 2019-Q1 | Increased 91 |
CYPRESS SEMICONDUCTOR CORP | 9.4M | $219M | 3.6% | — | — | 3 qtrssince 2019-Q2 | Decreased 0 |
TIFFANY & CO NEW | 1.4M | $192.8M | 3.2% | — | — | 1 qtr | New 85 |
MELLANOX TECHNOLOGIES LTD | 1.3M | $153.3M | 2.5% | — | — | 4 qtrssince 2019-Q1 | Decreased 0 |
| 13.5M | $146.9M | 2.4% | — | — | — | Increased — | |
TURQUOISE HILL RESOURCES LTD | 183.6M | $135.2M | 2.2% | — | — | 4 qtrssince 2019-Q1 | Increased 54 |
ESPERION THERAPEUTICS INC NE | 2.3M | $134.4M | 2.2% | $40.11 | +49.14% | 4 qtrssince 2019-Q1 | Decreased 0 |
| 1.9M | $124.5M | 2.0% | — | — | — | New — | |
| 35.6M | $107M | 1.8% | — | — | 1 qtr | New 69 | |
BOEING CO/THE | 258,172 | $84.1M | 1.4% | $323.83 | 0.00% | 1 qtr | New 68 |
| 615,000 | $82.2M | 1.3% | — | — | — | New — | |
| 250,000 | $80.5M | 1.3% | — | — | — | Increased — | |
| 415,000 | $79.3M | 1.3% | — | — | — | Increased — | |
MEDICINES CO | 780,500 | $66.3M | 1.1% | — | — | 1 qtr | New 68 |
| 1.8M | $65.7M | 1.1% | — | — | — | Decreased — |
Pentwater Capital Management LP manages $6.1B across 151 positions as of Q4 2019. Top holdings: STATE STREET SPDR S&P 500 ETF (29.4%), ZAYO (4.9%), MELLANOX TECHNOLOGIES LTD (4.9%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.
Active quarter - 36 new positions, 39 exits, 22 increased. Top move: PCG (INCREASED, conviction 91). Portfolio: $6.1B across 151 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer